Embedded Files
Publication list
Publication list
0. Park JH, Park SJ, Park J, Choi JU, Kweon S, Lee NK, Ko YG, Cho YS, Kim SY, Kim HR*, Byun Y. A novel gemcitabine prodrug with albumin binding property for KRAS mutant pancreatic cancer targeting., (In preparation) Corresponding Author
0. Park JH, Park SJ, Park J, Choi JU, Kweon S, Lee NK, Ko YG, Cho YS, Kim SY, Kim HR*, Byun Y. A novel gemcitabine prodrug with albumin binding property for KRAS mutant pancreatic cancer targeting., (In preparation) Corresponding Author
1.Lim G*, Kim HR*, Yoo C*, Oh YK, Park YS, Park S, Jang S, Priscilla L, Lee DY, Mucoadhesive and self-assembled chitosan oligosaccharide-glycyrrhizin nanoparticle for oral nanotherapeutic in inflammatory bowel disease., ACS Nano (IF: 15.8, Materials Science, Multidisciplinary 6 2025, Aug 13, First author
1.Lim G*, Kim HR*, Yoo C*, Oh YK, Park YS, Park S, Jang S, Priscilla L, Lee DY, Mucoadhesive and self-assembled chitosan oligosaccharide-glycyrrhizin nanoparticle for oral nanotherapeutic in inflammatory bowel disease., ACS Nano (IF: 15.8, Materials Science, Multidisciplinary 6 2025, Aug 13, First author
https://doi.org/10.1021/acsnano.5c09985
2. Lim H, Ma G, Jeong Y, Lee JH, Lee JH, Yang SB, Choi JU, Km HR*, Park J*. Tumor targeting in situ aggregation of nanoparticle-to-nanoparticle strategy to simultaneously induce ferroptosis and immunogenic cell death using complementary heparin and protamine molecules., Nano Today (IF:17.4, Materials science, multidisciplinary 5.4 %), 2024 Jun, 57: 102355. doi: 10.1016/j.nantod.2024.102355, *Corresponding authors
2. Lim H, Ma G, Jeong Y, Lee JH, Lee JH, Yang SB, Choi JU, Km HR*, Park J*. Tumor targeting in situ aggregation of nanoparticle-to-nanoparticle strategy to simultaneously induce ferroptosis and immunogenic cell death using complementary heparin and protamine molecules., Nano Today (IF:17.4, Materials science, multidisciplinary 5.4 %), 2024 Jun, 57: 102355. doi: 10.1016/j.nantod.2024.102355, *Corresponding authors
3. Park SJ, Cho YS, Lee J, Kim SY, Byun Y, Park J*, Kim HR*, An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer, J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2025 Nov, 389, 114380, doi: 10.1016/j.jconrel.2025.114380, Corresponding author
3. Park SJ, Cho YS, Lee J, Kim SY, Byun Y, Park J*, Kim HR*, An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer, J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2025 Nov, 389, 114380, doi: 10.1016/j.jconrel.2025.114380, Corresponding author
4. Kim HR*, Park SJ*, Cho YS, Choi JU, Park J, Kweon S, Lee NK, Knowledge M. Moyo, Chung SW, Ko YG, Yeo JH, Lee J, Kim SY, Byun Y. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 Jun 20:372:176-193. doi: 10.1016/j.jconrel.2024.06.028. *First authors
4. Kim HR*, Park SJ*, Cho YS, Choi JU, Park J, Kweon S, Lee NK, Knowledge M. Moyo, Chung SW, Ko YG, Yeo JH, Lee J, Kim SY, Byun Y. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 Jun 20:372:176-193. doi: 10.1016/j.jconrel.2024.06.028. *First authors
5. Kim HR*, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 ePub, *First author
5. Kim HR*, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 ePub, *First author
https://doi.org/10.1016/j.jconrel.2024.07.074
6. Cho YS*, Kim HR*, Park SJ, Chung SW, Ko YG, Yeo JH, Lee J, Kim SK, Choi JU, Kim SY, Byun Y. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer, Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2022 Oct; 289, 121783 *First authors
6. Cho YS*, Kim HR*, Park SJ, Chung SW, Ko YG, Yeo JH, Lee J, Kim SK, Choi JU, Kim SY, Byun Y. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer, Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2022 Oct; 289, 121783 *First authors
7. Kim HR*, Cho YS*, Chung SW, Choi JU, Ko YG, Park SJ, Kim SY, Byun Y. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr 22; 346:136-147. doi: 10.1016/j.jconrel.2022.04.014. *First authors
7. Kim HR*, Cho YS*, Chung SW, Choi JU, Ko YG, Park SJ, Kim SY, Byun Y. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr 22; 346:136-147. doi: 10.1016/j.jconrel.2022.04.014. *First authors
8. Shrestha S, Giri A, Shrestha P, Kweon S, Hong IS, Kwon TK, Kang JS, Jeong JH, Kim HR*, Yook S*, CD44-targeted nanoparticles for remodeling the tumor microenvironment in a 3D macrophage-enbedded ovarian cancer stem cell model., International Journal of Pharmaceutics (IF: 5.5, Pharmacology & Pharmacy 9.6 %), 2025 Mar, *Corresponding authors
9. Gong SJ*, Kim HR*, Park YJ, and Kim JE, Recent trends in continuous manufacturing and digitalization in pharmaceutical process development and manufacturing, Journal of Pharmaceutical Investigation (IF: 5.3, Pharmacology & Pharmacy 17.2 %), 2025 Feb 07; doi: 10.1007/s40005-025-00728-8 *Equal contributor as first authors
10. Nisi Zhang, Jai Woong Seo, Elise Robinson, Angelie Rivera-Rodriguez, James Wang, Yutong Guo ,Debra K. Czerwinski, Ha Rin Kim, Spencer K. Tumbale, Marina N. Raie, Basit L. Jan , Gocke Engudar, Adrienne Salets, Il Minn, Martin G. Pomper, Ronald Levy, Katherine W. Ferrara, Development of an in situ CAR-T cell protocol through optical and PSMA targeted PET imaging, PNAS, 2025 May 7
11. Lee JH, Yang SB, Park SJ, Kweon S, Ma G, Seo M, Kim HR, Kang TB, Lim JH, Park J. Cell-penetrating peptide like anti-programmed cell death-ligand 1 peptide conjugate-based self-assembled nanoparticles for immunogenic photodynamic therapy, ACS Nano, 2025 Jan, 19, 2: 2870-2889 ACS Nano (IF: 15.8, Materials Science, Multidisciplinary 6 %), 2025 Jan, 19; 2870-2889. doi: 10.1021/acsnano.4c16128
12. Park SJ, Kweon S, Knowledge M. Moyo, Kim HR, Park J, Choi JU, Kim BM, Park JW, Byun Y. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2024 Oct, 310:122625. doi: 10.1016/j.biomaterials.2024.122625
12. Park SJ, Kweon S, Knowledge M. Moyo, Kim HR, Park J, Choi JU, Kim BM, Park JW, Byun Y. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2024 Oct, 310:122625. doi: 10.1016/j.biomaterials.2024.122625
13. Cho YS*, Cho H*, Kim HR, Park SJ, Yeo JH, Ko YG, Lee J, Kim SY, Kim K, Byun Y. Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment, J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024; 376:829-841. doi: 10.1016/j.jconrel.2024.10.070
14. Lee KJ, Lee YM, Yang SB, Lee JH, Kim HR, Lim JH, Park J. A novel chemically engineered multifunctional statin conjugate as self-assembled nanoparticles inhibiting bile acid transporters, J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 Aug; 372:885-900. doi: 10.1016/j.jconrel.2024.07.008
15. Shrestha P, Pathak S, Chaudhary D, Regmi S, Shrestha M, Raut P.K, Kim JY, Orive G, Kim HR, Lee NK, Kweon S, Park J, Choi JU, Yook S, Jeong JH, PEGylation-based surface engineering of islets with microparticles co-delivery for enhanced engraftment in streptozocin-induced hyperglycemic murine model, Chemical Engineering Journal, 2025 July 31;166657, doi: 10.1016/j.cej.2025.166657
16. Cho YS, Kim GC, Lee HM, Kim B, Kim HR, Chung SW, Chang HW, Ko YG, Lee YS, Kim SW, Byun Y, Kim SY. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr; 344:26-38. doi: 10.1016/j.jconrel.2022.02.026.
16. Cho YS, Kim GC, Lee HM, Kim B, Kim HR, Chung SW, Chang HW, Ko YG, Lee YS, Kim SW, Byun Y, Kim SY. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr; 344:26-38. doi: 10.1016/j.jconrel.2022.02.026.
17. Lee NK, Choi JU, Kim HR, Chung SW, Ko YG, Cho YS, Park SJ, Lee EJ, Kim SY, Kim IS, Byun Y. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2021 Oct;277:121105. doi: 10.1016/j.biomaterials.2021.121105.
17. Lee NK, Choi JU, Kim HR, Chung SW, Ko YG, Cho YS, Park SJ, Lee EJ, Kim SY, Kim IS, Byun Y. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2021 Oct;277:121105. doi: 10.1016/j.biomaterials.2021.121105.
18. Choi JU, Kim JY, Chung SW, Lee NK, Park J, Kweon S, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8%), 2021 Aug 10;336:181-191. doi: 10.1016/j.jconrel.2021.06.019.
18. Choi JU, Kim JY, Chung SW, Lee NK, Park J, Kweon S, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8%), 2021 Aug 10;336:181-191. doi: 10.1016/j.jconrel.2021.06.019.
19. Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2019 Feb 28;296:241-249. doi: 10.1016/j.jconrel.2019.01.020.
19. Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2019 Feb 28;296:241-249. doi: 10.1016/j.jconrel.2019.01.020.
20. Chung SW, Cho YS, Choi JU, Kim HR, Won TH, Kim SY, Byun Y. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2019 Feb;192:109-117. doi: 10.1016/j.biomaterials.2018.11.001.
20. Chung SW, Cho YS, Choi JU, Kim HR, Won TH, Kim SY, Byun Y. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2019 Feb;192:109-117. doi: 10.1016/j.biomaterials.2018.11.001.
21. Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. Adv Sci (Weinh) (IF: 17.521, Materials science, multidisciplinary 6.8 %), 2018 Jun 5;5(7):1800368. doi: 10.1002/advs.201800368.
21. Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. Adv Sci (Weinh) (IF: 17.521, Materials science, multidisciplinary 6.8 %), 2018 Jun 5;5(7):1800368. doi: 10.1002/advs.201800368.
Page updated
Google Sites
Report abuse